The present invention aims at providing a
mucosal vaccine composition that can be administered to an intraoral
mucous membrane, ocular
mucous membrane, ear
mucous membrane, genital mucous membrane, pharyngeal mucous membrane,
respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane,
gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a
mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane,
respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane,
gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one
antigen; and as an
adjuvant, a
lipopolysaccharide derived from at least one
gram-negative bacterium selected from the group consisting of
Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus,
Gluconacetobacter,
Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia,
Pseudomonas,
Achromobacter, Bacillus, Methanoculleus, Methanosarcina,
Clostridium,
Micrococcus,
Flavobacterium,
Pantoea,
Acetobacter,
Zymomonas,
Xanthomonas, and
Enterobacter, or a salt thereof.